Complement system is activated in stenotic aortic valves

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 190-200

  Helske, Satu ^a   Oksjoki, Riina ^a   Lindstedt, Ken A ^a   Lommi, Jyri ^b   Turto, Heikki ^b   Werkkala, Kalervo ^b   Kupari, Markku ^b   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anaphylatoxin; Aortic stenosis; Complement; Inflammation; Valve

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5B; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AORTA VALVE STENOSIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AORTIC VALVE STENOSIS; CELLS, CULTURED; COMPLEMENT C3; COMPLEMENT C5A; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MEMBRANE PROTEINS; RECEPTORS, COMPLEMENT; UP-REGULATION;

EID: 38049027265     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.040     Document Type: Article

References (50)

1. Lindroos M., Kupari M., Valvanne J., et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15 (1994) 865-870
2. Olsson M., Thyberg J., and Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 (1999) 1218-1222
3. O'Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16 (1996) 523-532
4. Mohler III E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 103 (2001) 1522-1528
5. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994) 844-853
6. Olsson M., Dalsgaard C.J., Haegerstrand A., et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 23 (1994) 1162-1170
7. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44 (2004) 1859-1866
8. Oksjoki R., Kovanen P.T., and Pentikainen M.O. Role of complement activation in atherosclerosis. Curr Opin Lipidol 14 (2003) 477-482
9. Niculescu F., and Rus H. Complement activation and atherosclerosis. Mol Immunol 36 (1999) 949-955
10. Vlaicu R., Niculescu F., Rus H.G., et al. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57 (1985) 163-177
11. Laine P., Pentikainen M.O., Wurzner R., et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 90 (2002) 404-408
12. Oksjoki R, Jarva H, Kovanen PT, et al. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions. Implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003.
13. Siegel J., Rent R., and Gewurz H. Interactions of C-reactive protein with the complement system I. Protamine-induced consumption of complement in acute phase sera. J Exp Med 140 (1974) 631-647
14. Bhakdi S. Complement and atherogenesis: the unknown connection. Ann Med 30 (1998) 503-507
15. Fujita T., Endo Y., and Nonaka M. Primitive complement system-recognition and activation. Mol Immunol 41 (2004) 103-111
16. Nataf S., Davoust N., Ames R.S., et al. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 162 (1999) 4018-4023
17. Zwirner J., Werfel T., Wilken H.C., et al. Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur J Immunol 28 (1998) 1570-1577
18. Hartmann K., Henz B.M., Kruger-Krasagakes S., et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89 (1997) 2863-2870
19. Schulman E.S., Post T.J., Henson P.M., et al. Differential effects of the complement peptides C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 81 (1988) 918-923
20. el-Lati S.G., Dahinden C.A., and Church M.K. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 102 (1994) 803-806
21. Takabayashi T., Vannier E., Burke J.F., et al. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 177 (1998) 1622-1628
22. Goodman M.G., Chenoweth D.E., and Weigle W.O. Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med 156 (1982) 912-917
23. Ember J.A., Sanderson S.D., Hugli T.E., et al. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 144 (1994) 393-403
24. Albrecht E.A., Chinnaiyan A.M., Varambally S., et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 164 (2004) 849-859
25. Oksjoki R, Laine P, Helske S, et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007.
26. Helske S., Syvaranta S., Kupari M., et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 27 (2006) 1495-1504
27. Seifert P.S., Hugo F., Hansson G.K., et al. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 60 (1989) 747-754
28. Torzewski J., Oldroyd R., Lachmann P., et al. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 16 (1996) 673-677
29. Nauta A.J., Daha M.R., Tijsma O., et al. The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 32 (2002) 783-792
30. Niculescu F., Badea T., and Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 142 (1999) 47-56
31. Kilgore K.S., Schmid E., Shanley T.P., et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 150 (1997) 2019-2031
32. Skowasch D., Schrempf S., Preusse C.J., et al. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 92 (2006) 495-498
33. Seifert P.S., Hugo F., Tranum-Jensen J., et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 172 (1990) 547-557
34. Bhakdi S., Dorweiler B., Kirchmann R., et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 182 (1995) 1959-1971
35. Fondard O., Detaint D., Iung B., et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26 (2005) 1333-1341
36. Helske S., Syvaranta S., Lindstedt K.A., et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 26 (2006) 1791-1798
37. Saad A.F., Virella G., Chassereau C., et al. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 47 (2006) 1975-1983
38. Pinckard R.N., Olson M.S., Giclas P.C., et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 56 (1975) 740-750
39. Mevorach D., Mascarenhas J.O., Gershov D., et al. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188 (1998) 2313-2320
40. Tanaka K., Sata M., Fukuda D., et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 46 (2005) 134-141
41. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14 (2005) 80-87
42. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 (1997) 630-634
43. Geertinger P., and Sorensen H. Complement as a factor in arteriosclerosis. Acta Pathol Microbiol Scand [A] 78 (1970) 284-288
44. Schmiedt W., Kinscherf R., Deigner H.P., et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18 (1998) 1790-1795
45. Persson L., Boren J., Robertson A.K., et al. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 24 (2004) 1062-1067
46. Holland M.C., Morikis D., and Lambris J.D. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs 5 (2004) 1164-1173
47. Novaro G.M., Tiong I.Y., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
48. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
49. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
50. Rajamannan N.M., and Otto C.M. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110 (2004) 1180-1182